Buried in the safety data was something unexpected: dysesthesia affecting 20.9% of patients at the highest dose
[12] [13] Pharmacologically, semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist
The pharmacokinetic parameters included area under the curve plasma concentrations (AUC), maximal plasma concentration (C max ), time to C max , half-life (t 1/2 ), and clearance
Clinical Insight Karla K
Materials checklist: what you need before starting Gather everything before you open the vial
Sonya Babu-Narayan, clinical director at the British Heart Foundation and consultant cardiologist, said: These intriguing results demonstrate that the benefits of medications like semaglutide on heart health go beyond weight loss alone. However, she commented: More research will be needed to unravel the other mechanisms of action behind the cardiovascular benefits beyond weight and fat loss, such as improvements in blood vessel health, control of blood pressure and blood sugar or inflammation